Pricing Policy Panic Persists; Subpoena Demands Vex Valeant
This article was originally published in Scrip
Executive Summary
Even as Wall Street analysts were trying to calm biotech investors on Sept. 28 after last week's panic over concerns Washington would try to control prices – triggered by the news that Turing Pharmaceuticals had increased by more than 5,000% the cost of its toxoplasmosis medicine Daraprim (pyrimethamine) – Democrats were turning up the heat, taking aim at Valeant Pharmaceuticals.